Alex King

Alex King

Three-decade investment professional with experience in US public stocks, leveraged buyouts and venture capital. CEO of Cestrian Capital Research, Inc.

Pfizer ( PFE ) – Q3 2025 Review

The Stock That Fell To Earth

Vertiv Holdings Q3 FY12/25 Earnings Review

Still Racking Up The Wins

Market On Open, Thursday 8 January

Wider, Deeper Coverage Starts Today

Metals On Open, Wednesday 7 January

BTFD x WW3

In Pursuit Of Entropy: The Trade Desk ($TTD) Q3 Earnings Review

What Next For The Worst Performing Stock Of 2025?

Market On Open, Tuesday 6 January

Goldilocks?

Q: Is There A Generational Opportunity In Biotech Stocks?

Biotech 2026 = Tech 2023?

Regeneron (REGN) – Q3 2025 Review

Eyeing A Breakout?

Getting A Little Too Exciting? Read On!

Don’t Sleep On Income Opportunities.

Market On Open, Sunday 4 January

DISCLAIMER: This note is intended for US recipients only and,